Adherence to Cholinesterase Inhibitors in Alzheimer's Disease: A Review

Adherence to cholinesterase inhibitors in Alzheimer's disease: a review.

BACKGROUND/AIMS Treatment adherence is a major problem in numerous medical conditions, and is a particular challenge in patients with Alzheimer's disease (AD). METHODS This non-systematic review summarises the current literature on factors that affect adherence to cholinesterase inhibitors, the mainstay of AD treatment. Articles listed on PubMed and published during the last 10 years were inc...

Review: cholinesterase inhibitors may be effective in Alzheimer disease.

Cholinesterase Inhibitors: Drugs Looking for a Disease?

0456 R andomized controlled trials (RCTs) are generally considered to be a robust form of evidence, free from bias, and the trial results are often used as a powerful tool to promote new drugs [1,2]. However, because the inclusion criteria for many RCTs are often very restrictive (for example, trials generally exclude patients with serious concomitant illnesses) and because patients in trials t...

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease

BACKGROUND A varying response to cholinesterase inhibitor (ChEI) treatment has been reported among patients with Alzheimer's disease (AD). Whether the individual-specific response, specific ChEI agent or dose affects mortality is unclear. We aimed to examine the relationship between the 6-month response to ChEI and lifespan. METHODS Six hundred and eighty-one deceased patients with a clinical...

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease

BACKGROUND CHRNA7 encodes the α7 nicotinic acetylcholine receptor subunit, which is important to Alzheimer's disease (AD) pathogenesis and cholinergic neurotransmission. Previously, CHRNA7 polymorphisms have not been related to cholinesterase inhibitors (ChEI) response. METHODS Mild to moderate AD patients received ChEIs were recruited from the neurology clinics of three teaching hospitals fr...